Targeting PDZ binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Adrenocortical carcinoma (ACC) is an aggressive orphan malignancy with less than 35% 5-year survival and 75% recurrence. Surgery remains the primary therapy and mitotane, an adrenolytic, is the only FDA approved drug with wide range toxicities and poor tolerability. There are no targeted agents available to date. For the last three decades, H295R cell line and its xenograft were the only available pre-clinical models. We recently developed two new ACC patient derived xenograft mouse models and corresponding cell lines (CU-ACC1 and CU-ACC2) to advance research in the field. Here, we have utilized these novel models along with H295R cells to establish the mitotic PDZ binding kinase (PBK) as a promising therapeutic target. PBK is overexpressed in ACC samples and correlates with poor survival. We show that PBK is regulated by FOXM1 and targeting PBK via shRNA decreased cell proliferation, clonogenicity, and anchorage independent growth in ACC cell lines. PBK silencing inhibited pAkt, pp38MAPK, and pH3 altering the cell cycle. Therapeutically, targeting PBK with the small molecule inhibitor HITOPK032 phenocopied PBK specific modulation of pAkt and pH3, but also induced apoptosis via activation of JNK. Consistent with in vitro findings, treatment of CU-ACC1 PDXs with HITOPK032 significantly reduced tumor growth by 5-fold (p<0.01). Treated tumor tissues demonstrated increased rates of apoptosis and JNK activation, with decreased pAkt and H3 phosphorylation, consistent with effects observed in ACC cell lines. Together these studies elucidate the mechanism of PBK in ACC tumorigenesis and establish the potential therapeutic potential of HITOPK032 in patients.